Preloading with atorvastatin before percutaneous coronary intervention in statin-naïve Asian patients with non-ST elevation acute coronary syndromes: A randomized study

Journal of Cardiology

Volumn 63, Issue 5, 2014, Pages 335-343

  Jang, Yangsoo ^a   Zhu, Junren ^b   Ge, Junbo ^b   Kim, Young Jo ^c   Ji, Chen ^d   Lam, William ^d  

^a Yonsei University College of Medicine   (South Korea)

^b FUDAN UNIVERSITY   (China)

^c Young Nam University Hospital   (South Korea)

^d PFIZER INC   (United States)

Author keywords

Acute coronary syndromes; Percutaneous coronary intervention; Preloading; Statin

Indexed keywords

ALANINE AMINOTRANSFERASE; ATORVASTATIN; C REACTIVE PROTEIN; CREATINE KINASE MB; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TROPONIN I;

ABNORMAL LABORATORY RESULT; ADULT; ANGIOCARDIOGRAPHY; ARTICLE; ASIAN; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL DISEASE; HEART DISEASE; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MUSCULOSKELETAL DISEASE; MYALGIA; NEUROLOGIC DISEASE; NON ST SEGMENT ELEVATION ACUTE CORONARY SYNDROME; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; RANDOMIZED CONTROLLED TRIAL; REVASCULARIZATION; UNSTABLE ANGINA PECTORIS; VASCULAR DISEASE;

ACUTE CORONARY SYNDROMES; PERCUTANEOUS CORONARY INTERVENTION; PRELOADING; STATIN;

ACUTE CORONARY SYNDROME; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CARDIOVASCULAR DISEASES; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PERCUTANEOUS CORONARY INTERVENTION; POSTOPERATIVE CARE; POSTOPERATIVE COMPLICATIONS; PREOPERATIVE CARE; PYRROLES; TIME FACTORS;

EID: 84899973037     PISSN: 09145087     EISSN: 18764738     Source Type: Journal    
DOI: 10.1016/j.jjcc.2013.09.012     Document Type: Article

References (35)

1. Patti G., Chello M., Candura D., Pasceri V., D'Ambrosio A., Covino E., Di Sciascio G. Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery: results of the ARMYDA-3 (Atorvastatin for Reduction of MYocardial Dysrhythmia After cardiac surgery) study. Circulation 2006, 114:1455-1461.
2. Patti G., Chello M., Pasceri V., Colonna D., Nusca A., Miglionico M., D'Ambrosio A., Covino E., Di Sciascio G. Protection from procedural myocardial injury by atorvastatin is associated with lower levels of adhesion molecules after percutaneous coronary intervention: results from the ARMYDA-CAMs (Atorvastatin for Reduction of MYocardial Damage during Angioplasty-Cell Adhesion Molecules) substudy. J Am Coll Cardiol 2006, 48:1560-1566.
3. Patti G., Pasceri V., Colonna G., Miglionico M., Fischetti D., Sardella G., Montinaro A., Di Sciascio G. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial. J Am Coll Cardiol 2007, 49:1272-1278.
4. Patti G., Nusca A., Chello M., Pasceri V., D'Ambrosio A., Vetrovec G.W., Di Sciascio G. Usefulness of statin pretreatment to prevent contrast-induced nephropathy and to improve long-term outcome in patients undergoing percutaneous coronary intervention. Am J Cardiol 2008, 101:279-285.
5. Patti G., Nusca A., Mangiacapra F., Gatto L., D'Ambrosio A., Di Sciascio G. Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity Predicts Outcome) study. J Am Coll Cardiol 2008, 52:1128-1133.
6. Hao P.P., Chen Y.G., Wang J.L., Ji W.Q., Xue L., Liu X.H., Wang X.L., Zhang Y. Meta-analysis of the role of high-dose statins administered prior to percutaneous coronary intervention in reducing major adverse cardiac events in patients with coronary artery disease. Clin Exp Pharmacol Physiol 2010, 37:496-500.
7. Zhang F., Dong L., Ge J. Effect of statins pretreatment on periprocedural myocardial infarction in patients undergoing percutaneous coronary intervention: a meta-analysis. Ann Med 2010, 42:171-177.
8. Winchester D.E., Wen X., Xie L., Bavry A.A. Evidence of pre-procedural statin therapy: a meta-analysis of randomized trials. J Am Coll Cardiol 2010, 56:1099-1109.
9. Merla R., Reddy N.K., Wang F.W., Uretsky B.F., Barbagelata A., Birnbaum Y. Meta-analysis of published reports on the effect of statin treatment before percutaneous coronary intervention on periprocedural myonecrosis. Am J Cardiol 2007, 100:770-776.
10. Mood G.R., Bavry A.A., Roukoz H., Bhatt D.L. Meta-analysis of the role of statin therapy in reducing myocardial infarction following elective percutaneous coronary intervention. Am J Cardiol 2007, 100:919-923.
11. Ebrahimi R., Saleh J., Toggart E., Shah A.P., Azmoon S., Babaei H., Lee J., Smith R., Movahed M.R., Rubin S.A. Effect of preprocedural statin use on procedural myocardial infarction and major cardiac adverse events in percutaneous coronary intervention: a meta-analysis. J Invasive Cardiol 2008, 20:292-295.
12. Yun K.H., Jeong M.H., Oh S.K., Rhee S.J., Park E.M., Lee E.M., Yoo N.J., Kim N.H., Ahn Y.K., Jeong J.W. The beneficial effect of high loading dose of rosuvastatin before percutaneous coronary intervention in patients with acute coronary syndrome. Int J Cardiol 2009, 137:246-251.
13. Sun Y., Qi G., Gao Y., Zhang H., Pang X., Zhao W., Zhang Z. Effect of different loading doses of atorvastatin on percutaneous coronary intervention for acute coronary syndromes. Can J Cardiol 2010, 26:481-485.
14. Yun K.H., Oh S.K., Rhee S.J., Yoo N.J., Kim N.H., Jeong J.W. 12-Month follow-up results of high dose rosuvastatin loading before percutaneous coronary intervention in patients with acute coronary syndrome. Int J Cardiol 2011, 146:68-72.
15. Tsunoda R., Sakamoto T., Kojima S., Ogata Y., Kitagwa A., Ogawa H. Recurrence of angina pectoris after percutaneous coronary intervention is reduced by statins in Japanese patients. J Cardiol 2011, 58:208-215.
16. Yun K.H., Shin S.N., Ko J.S., Rhee S.J., Kim N.H., Oh S.K., Jeong J.W. Rosuvastatin-induced high-density lipoprotein changes in patients who underwent percutaneous coronary intervention for non-ST-segment elevation acute coronary syndrome. J Cardiol 2012, 60:383-388.
17. Ge J., Kim Y.J., Jang Y.S., Zhu J., Marschner I.C., Lam W. Design and rationale of a study in Asia of atorvastatin pretreatment in patients undergoing percutaneous coronary intervention for non-ST elevation acute coronary syndromes. J Cardiol 2010, 55:303-308.
18. Anderson J.L., Adams C.D., Antman E.M., Bridges C.R., Califf R.M., Casey D.E., Chavey W.E., Fesmire F.M., Hochman J.S., Levin T.N., Lincoff A.M., Peterson E.D., Theroux P., Wenger N.K., Wright R.S., et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction. Circulation 2007, 116:e148-e304.
19. Thygesen K., Alpert J.S., White H.D. Universal definition of myocardial infarction. Eur Heart J 2007, 28:2525-2538.
20. Veselka J., Zemanek D., Hajek P., Maly M., Adlova R., Martinkovicova L., Tesar D. Effect of two-day atorvastatin pretreatment on the incidence of periprocedural myocardial infarction following elective percutaneous coronary intervention: a single-center, prospective, and randomized study. Am J Cardiol 2009, 104:630-633.
21. Cannon C.P., Braunwald E., McCabe C.H., Rader D.J., Rouleau J.L., Belder R., Joyal S.V., Hill K.A., Pfeffer M.A., Skene A.M., Pravastatin or Atorvastatin Evaluation and Infection Therapy - Thrombolysis in Myocardial Infarction 22 Investigators Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004, 350:1495-1504.
22. Gibson C.M., Pride Y.B., Hochberg C.P., Sloan S., Sabatine M.S., Cannon C.P. Effect of intensive statin therapy on clinical outcomes among patients undergoing percutaneous coronary intervention for acute coronary syndrome. PCI-PROVE IT: A PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy - Thrombolysis in Myocardial Infarction 22) Substudy. J Am Coll Cardiol 2009, 54:2290-2295.
23. Schwartz G.G., Olsson A.G., Ezekowitz M.D., Ganz P., Oliver M.F., Waters D., Zeiher A., Chaitman B.R., Leslie S., Stern T., Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001, 285:1711-1718.
24. Patti G., Cannon C.P., Murphy S.A., Mega S., Pasceri V., Briguori C., Colombo A., Yun K.H., Jeong M.H., Kim J.S., Choi D., Bozbas H., Kinoshita M., Fukuda K., Jia X.W., et al. Clinical benefit of statin pretreatment in patients undergoing percutaneous coronary intervention: a collaborative patient-level meta-analysis of 13 randomized studies. Circulation 2011, 123:1622-1632.
25. Ko D.T., Wijeysundera H.C., Yun L., Austin P.C., Cantor W.J., Tu J.V. Effectiveness of preprocedural statin therapy on clinical outcomes for patients with stable coronary artery disease after percutaneous coronary interventions. Circ Cardiovasc Qual Outcomes 2011, 4:459-466.
26. Levine G.N., Bates E.R., Blankenship J.C., Bailey S.R., Bittl J.A., Cercek B., Chambers C.E., Ellis S.G., Guyton R.A., Hollenberg S.M., Khot U.N., Lange R.A., Mauri L., Mehran R., Moussa I.D., et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation 2011, 124:e574-e651.
27. European Association for Cardiovascular Prevention & Rehabilitation, Reiner Z., Catapano A.L., De Backer G., Graham I., Taskinen M.R., Wiklund O., Agewall S., Alegria E., Chapman M.J., Durrington P., Erdine S., Halcox J., Hobbs R., Kjekshus J., et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011, 32:1769-1818.
28. Grines C.L., Dixon S. A nail in the coffin of troponin measurements after percutaneous coronary intervention. J Am Coll Cardiol 2011, 57:662-663.
29. Lim C.C., van Gaal W.J., Testa L., Cuculi F., Arnold J.R., Karamitsos T., Francis J.M., Petersen S.E., Digby J.E., Westaby S., Antoniades C., Kharbanda R.K., Burrell L.M., Neubauer S., Banning A.P. With the universal definition, measurement of creatine kinase-myocardial band rather than troponin allows more accurate diagnosis of periprocedural necrosis and infarction after coronary intervention. J Am Coll Cardiol 2011, 57:653-661.
30. Thygesen K., Alpert J.S., Jaffe A.S., Simoons M.L., Chaitman B.R., White H.D. Third universal definition of myocardial infarction. Circulation 2012, 126:2020-2035.
31. LaRosa J.C., Grundy S.M., Waters D.D., Shear C., Barter P., Fruchart J.C., Gotto A.M., Greten H., Kastelein J.J., Shepherd J., Wenger N.K., Treating to New Targets (TNT) Investigators Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005, 352:1425-1435.
32. Kurogi K., Sugiyama S., Sakamoto K., Tayama S., Nakamura S., Biwa T., Matsui K., Ogawa H., COMPACT-CAD Investigators Comparison of pitavastatin with atorvastatin in increasing HDL-cholesterol and adiponectin in patients with dyslipidemia and coronary artery disease: the COMPACT-CAD study. J Cardiol 2013, 62:87-94.
33. Japan Cholesterol Lowering Atorvastatin Study (J-CLAS) Group Efficacy of atorvastatin in primary hypercholesterolemia. Am J Cardiol 1997, 79:1248-1252.
34. Wang K.Y., Ting C.T. A randomized, double-blind, placebo-controlled, 8-week study to evaluate the efficacy and safety of once daily atorvastatin (10mg) in patients with elevated LDL-cholesterol. Jpn Heart J 2001, 42:725-738.
35. Wu C.C., Sy R., Tanphaichitr V., Hin A.T., Suyono S., Lee Y.T. Comparing the efficacy and safety of atorvastatin and simvastatin in Asians with elevated low-density lipoprotein-cholesterol-a multinational, multicenter, double-blind study. J Formos Med Assoc 2002, 101:478-487.